Spoiler: You probably won't be able to live forever, even if you want to. How about settling for a life free from age-related ailments like Alzheimer's or arthritis instead?
Aducanumab is approved in the United States, but the EU's regulatory authority is blocking its use. The drug is designed to combat amyloid beta plaques in the brain that are typical of Alzheimer's disease.
The drug aducanumab could be approved in the US and EU soon. It effectively combats the amyloid beta plaques in the brain that are indicative of Alzheimer's disease. But does it also slow down memory loss?
Alzheimer s Disease
Alzheimer s was discovered more than 100 years ago, but a cure has still not been found.
About 50 million people worldwide have dementia, according to the WHO, and Alzheimer s contributes to up to 70% of cases. The WHO estimates that the total number of people with dementia will reach 82 million in 2030 and 152 million in 2050. It s now among the top 10 causes of death, according to the WHO s 2019 Global Health Estimates.
Before the study, the scientists established that in the brains of Alzheimer s patients, key elements of the machinery that allows protein production were depleted in the hippocampus. This led them to think that protein synthesis may also be impaired.